Equities
Health CarePharmaceuticals & Biotechnology
  • Price (DKK)296.70
  • Today's Change3.40 / 1.16%
  • Shares traded400.76k
  • 1 Year change-14.94%
  • Beta1.1188
Data delayed at least 15 minutes, as of Sep 17 2019 15:59 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

As of Sep 13, 2019, the consensus forecast amongst 17 polled investment analysts covering Novozymes A/S advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts improved on Feb 15, 2018. The previous consensus forecast advised that the company would underperform Novozymes A/S.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.
RecommendationsLatest
Buy2
Outperform2
Hold5
Underperform4
Sell4

Share price forecast

The 16 analysts offering 12 month price targets for Novozymes A/S have a median target of 282.50, with a high estimate of 390.00 and a low estimate of 250.00. The median estimate represents a -3.68% decrease from the last price of 293.30.
High31.4%390.00
Med-4.8%282.50
Low-15.7%250.00

Dividends

In 2018, Novozymes A/S reported a dividend of 5.00 DKK, which represents a 11.11% increase over last year. The 18 analysts covering the company expect dividends of 5.37 DKK for the upcoming fiscal year, an increase of 7.40%.
Div growth (TTM)11.11%
More ▼

Earnings history & estimates

On Aug 08, 2019, Novozymes A/S reported 2nd quarter 2019 earnings of 3.12 per share. This result was in line with the consensus of the 7 analysts following the company and exceeded last year's 2nd quarter results by 17.74%.
The next earnings announcement is expected on Oct 23, 2019.
Average growth rate+5.43%
Novozymes A/S reported annual 2018 earnings of 11.03 per share on Jan 24, 2019.
The next earnings announcement from Novozymes A/S is expected the week of Jan 23, 2020.
Average growth rate+8.36%
More ▼

Revenue history & estimates

Novozymes A/S had 2nd quarter 2019 revenues of 3.46bn. This missed the 3.60bn consensus estimate of the 7 analysts following the company. This was 1.14% below the prior year's 2nd quarter results.
Average growth rate-0.21%
Novozymes A/S had revenues for the full year 2018 of 14.39bn. This was 0.97% below the prior year's results.
Average growth rate+3.79%
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.